SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced the appointment of Jesse Wu to the company’s Board of Directors.
“We are proud to welcome Jesse to the LianBio team,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. “With his extensive global leadership experience and deep expertise in China and the Asia Pacific region, we are confident he will be a tremendous asset to LianBio as we continue to advance our diverse pipeline of potentially transformative medicines for patients in China and throughout Asia.”
Mr. Wu brings over 30 years of experience in multi-national business management. He currently serves as Non-Executive Director of AptarGroup, Inc., and advises private equity firms focusing on healthcare related industries. Previously, Mr. Wu served in roles of increasing responsibility at Johnson & Johnson, where he served as Chairman of Johnson & Johnson China, Worldwide Chairman of Johnson & Johnson consumer health business, and a member of the Johnson & Johnson Management Committee. Earlier in his career, Mr. Wu held positions at Procter & Gamble and PepsiCo in the U.S and Europe. Mr. Wu also serves as a member of the Board of Visitors at Duke University’s Fuqua School of Business. Mr. Wu was a two-time recipient of Magnolia Award, an honor conferred by the Shanghai government for his contributions to the city’s economic development.
“I’m excited to be joining LianBio at this time of growth for the company,” said Mr. Wu. “I look forward to working with the team to expand our footprint and capabilities in China and deliver medicines to patients with significant unmet medical needs.”
Mr. Wu received an undergraduate degree in economics from National Chengchi University in Taiwan, and an MBA degree from Duke University’s Fuqua School of Business.
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit www.lianbio.com.